Literature DB >> 26417173

Pharmaceutical Approval Update.

Kunj Gohil.   

Abstract

Sacubitril/valsartan (Entresto) for chronic heart failure; brexpiprazole (Rexulti) for major depressive disorder and schizophrenia; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis involving specific CFTR mutations.

Entities:  

Year:  2015        PMID： 26417173      PMCID： PMC4571842     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.

Authors:  Alison E Fohner; Ellen M McDonagh; John P Clancy; Michelle Whirl Carrillo; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-01       Impact factor: 2.089

2.  Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.

Authors:  Xiaojiao Xue; Venkateshwar Mutyam; Amita Thakerar; James Mobley; Robert J Bridges; Steven M Rowe; Kim M Keeling; David M Bedwell
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.